Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy

Chintan V. Dave(Brigham and Women's Hospital), Elisabetta Patorno(Brigham and Women's Hospital), Allison B. Goldfine(Novartis (Switzerland)), Robert J. Glynn(Brigham and Women's Hospital), Angela Tong(New York University), Seoyoung C. Kim(Kookmin University)

Circulation

December 11, 2020

10.1161/circulationaha.120.047965

Cited by 93

Related Papers

A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home Admission

|Journal of Gerontology|1994|9.7k

Clinical Update: Cardiovascular Disease in Diabetes Mellitus

|Circulation|2016|1.1k

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

|The Lancet|2017|881

Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism

|Obesity|2009|590

Activation of Vascular Protein Kinase C-β Inhibits Akt-Dependent Endothelial Nitric Oxide Synthase Function in Obesity-Associated Insulin Resistance

|Diabetes|2006|216